Prion protein metabolism refers to the cellular processes involved in the synthesis, folding, trafficking, and degradation of the cellular prion protein (PrP^C) and its pathological isoform (PrP^Sc). Dysregulation of prion protein metabolism is central to prion diseases and has implications for understanding broader neurodegenerative processes.
The cellular prion protein is a glycosylphosphatidylinositol (GPI)-anchored protein encoded by the PRNP gene located on chromosome 20p13.
Structure:
- N-terminal signal peptide (residues 1-23)
- Octarepeat region (residues 51-91)
- Central hydrophobic domain (residues 106-126)
- C-terminal GPI anchor signal (residues 231-253)
- Two N-linked glycosylation sites (Asn181, Asn197)
- One disulfide bond (Cys179-Cys214)
Normal Function:
- Copper ion binding and homeostasis
- Neuronal protection against oxidative stress
- Synaptic function and plasticity
- Cell adhesion and signaling
- Neurogenesis
The scrapie isoform (PrP^Sc) is the pathogenic, misfolded form of the prion protein.
Key Characteristics:
- Conformational change: α-helical PrP^C converts to β-sheet-rich PrP^Sc
- Aggregation: Forms amyloid fibrils and plaques
- Resistance: Denotes protease resistance (Proteinase K resistant core)
- Infectivity: Can template further conversion of PrP^C
- Strain diversity: Different conformations cause distinct disease phenotypes
¶ Biosynthesis and Folding
flowchart TD
APRNP G["ene Transcription"] --> B["mRNA Export"]
B --> CRibosome T["ranslation"]
C --> DER S["ignal Peptide Cleavage"]
D --> EPrP^C F["olding in ER"]
E --> FQuality C["ontrol in ER"]
F --> GGlycosylation in G["olgi"]
G --> HGPI A["nchor Addition"]
H --> ITrafficking to P["lasma Membrane"]
I --> JEndocytosis/R["ecycling"]
J --> K["Degradation"]
- ER-associated degradation (ERAD): Targets misfolded PrP for ubiquitin-proteasome degradation
- Unfolded protein response (UPR): Activated by ER stress from PrP misfolding
- Molecular chaperones: BiP, GRP94, PDI assist in folding
- ER export: Proper folding required for exit from ER
| Modification | Location | Function |
|--------------|----------|----------|
| N-linked glycosylation | Asn181, Asn197 | Protein stability, trafficking |
| GPI anchor | C-terminus | Membrane anchoring |
| Disulfide bond | Cys179-Cys214 | Structural stability |
| Signal peptide cleavage | N-terminus | Secretion |
| GPI remodeling | After endocytosis | Recycling |
- Biosynthetic pathway: ER → Golgi → plasma membrane
- Endocytic pathway: Clathrin-mediated endocytosis
- Recycling pathway: Endosome → plasma membrane
- Degradation pathway: Lysosomal degradation
The conversion of PrP^C to PrP^Sc follows a template-assisted mechanism:
- Initiation: Spontaneous formation of PrP^Sc seed (rare event)
- Elongation: Addition of PrP^C monomers to PrP^Sc template
- Fragmentation: Breakage of fibrils increases growth sites
- Amplification: Exponential increase in PrP^Sc
PrP^C (cellular):
- 40% α-helices
- Minimal β-sheet content
- Soluble monomer
- Protease sensitive
PrP^Sc (scrapie):
- 40-50% β-sheets
- Reduced α-helices
- Aggregate-forming
- Protease resistant (partial)
- Octarepeat region (residues 51-91): Copper binding, mutation susceptibility
- Central hydrophobic region (residues 106-126): Membrane interaction, aggregation
- C-terminal domain: Core of PrP^Sc formation
| Mutation |
Disease Association |
Effect |
| P102L |
GSS |
Reduced PrP^C stability |
| A117V |
GSS |
Altered glycosylation |
| D178N |
FFI/familial CJD |
Impaired trafficking |
| E200K |
Familial CJD |
Enhanced aggregation |
| M232R |
Familial CJD |
GPI anchor defect |
| F198S |
GSS |
Protein instability |
- M129V: Valine at position 129 modulates disease susceptibility and incubation period
- PRNP promoter polymorphisms: Affect expression levels
- ERAD-mediated degradation of misfolded PrP
- Polyubiquitination targets PrP for proteasomal degradation
- Impaired UPS contributes to PrP^Sc accumulation
- Autophagy-lysosome pathway degrades PrP^C and PrP^Sc
- Macroautophagy and chaperone-mediated autophagy (CMA) involved
- Lysosomal dysfunction enhances PrP^Sc aggregation
- Extracellular vesicles: PrP release and clearance
- Microglial phagocytosis: Cellular uptake and degradation
- Blood-brain barrier transport: Peripheral clearance
| Disease |
Etiology |
Key Features |
| Creutzfeldt-Jakob Disease (CJD) |
Sporadic, genetic, iatrogenic |
Rapid progression, dementia, ataxia |
| Variant CJD (vCJD) |
Dietary exposure |
Psychiatric symptoms, kuru-type plaques |
| Fatal Familial Insomnia (FFI) |
D178N/Met129 |
Sleep disturbance, autonomic failure |
| Gerstmann-Sträussler-Scheinker (GSS) |
Genetic |
Cerebellar ataxia, long duration |
| Kuru |
Ritualistic exposure |
Cerebellar ataxia, laughing death |
- Scrapie (sheep and goats)
- Bovine spongiform encephalopathy (BSE)
- Chronic wasting disease (CWD) (cervids)
- Transmissible mink encephalopathy (TME)
- PrP^C expression: Gene silencing, antisense oligonucleotides
- PrP^C to PrP^Sc conversion: Small molecule inhibitors
- PrP^Sc aggregation: Anti-aggregation compounds
- PrP^Sc clearance: Immunotherapy, autophagy enhancers
- Degradation pathways: UPS/lysosome modulators
- Antisense therapy: PRNP knockdown in mice prevents disease
- Antibodies: Anti-PrP antibodies block conversion
- Small molecules: Quinacrine, pentosan polysulfate
- Gene therapy: CRISPR-based approaches
Prion-like mechanisms have been proposed in:
- Alzheimer's disease: Aβ and tau propagation
- Parkinson's disease: α-synuclein spreading
- ALS: SOD1, TDP-43 aggregation
- Huntington's disease: Mutant huntingtin aggregation
The concept of template-guided misfolding discovered in prion diseases has revolutionized understanding of protein aggregation in neurodegeneration.
The concept of prion-like propagation, first discovered in prion diseases, has been extended to other neurodegenerative conditions where misfolded proteins can template the conversion of their normal counterparts.
The spreading of Aβ pathology follows patterns consistent with trans-synaptic transmission:
- Seed formation: Aβ oligomers serve as nucleation foci
- Template-directed conversion: Normal Aβ monomers convert to pathological forms
- Axonal transport: Pathological Aβ travels along neuronal connections
- Network propagation: Connected neurons acquire pathology in sequence
Evidence from animal models shows that injection of brain extracts from AD patients into transgenic mice induces amyloid plaque formation in anatomically connected regions, demonstrating the prion-like nature of Aβ propagation.
Like Aβ, pathological tau spreads through brain networks in a connectivity-dependent manner:
- Oligomer uptake: Neurons internalize tau oligomers from extracellular space
- Intracellular templating: Endogenous tau converts to pathological conformers
- Trans-synaptic spread: Pathological tau transfers to connected neurons
- Temporal progression: Follows Braak staging patterns in human disease
The epidemic spreading model of tau pathology provides strong evidence for network-based propagation mechanisms that parallel prion disease progression.
¶ Membrane Composition and Lipid Rafts
The prion protein is enriched in lipid rafts, membrane microdomains rich in cholesterol and sphingolipids.
Key factors:
- Cholesterol levels modulate PrP^Sc formation
- Specific lipids promote conformational conversion
- Membrane fluidity affects conversion efficiency
- Glycosphingolipids stabilize pathological conformers
Cellular chaperone systems influence prion metabolism:
| Chaperone |
Function |
Effect on Prion Conversion |
| BiP/GRP78 |
ER chaperone |
Promotes proper folding |
| GRP94 |
ER chaperone |
Limits aggregation |
| PDI |
Protein disulfide isomerase |
Facilitates folding |
| Hsp90 |
Cytosolic chaperone |
Modulates degradation |
| Hsp70 |
Cytosolic chaperone |
Targets misfolded PrP |
The prion protein undergoes extensive PTMs that influence its conversion:
- N-linked glycosylation: Two sites (Asn181, Asn197) affect folding and trafficking
- GPI anchor composition: Variations in lipid moiety influence raft localization
- Disulfide bond formation: Cys179-Cys214 stabilizes the C-terminal domain
- Signal peptide cleavage: N-terminal processing affects aggregation propensity
Prion protein is highly enriched at synapses, and PrP^Sc accumulation disrupts synaptic function:
- Glutamate receptor dysfunction: Impaired NMDA and AMPA signaling
- Synaptic vesicle cycle disruption: Altered neurotransmitter release
- Dendritic spine loss: Reduced synaptic connectivity
- Calcium homeostasis perturbation: Dysregulated intracellular calcium
Prion disease progression involves:
- Mitochondrial dysfunction: Impaired oxidative phosphorylation
- ATP depletion: Energy crisis in neurons
- Oxidative stress: Increased reactive oxygen species
- ER stress: Activation of unfolded protein response
Prion infection overwhelms cellular quality control:
- Proteasome inhibition: Impaired degradation capacity
- Autophagy disruption: Blocked lysosomal clearance
- Aggregate accumulation: Sequestration of cellular factors
- Stress granule formation: RNA processing defects
¶ Strain Diversity and Propagation
Prion diseases exhibit strain diversity—different conformations of PrP^Sc cause distinct clinical phenotypes:
| Strain |
Species |
Incubation |
Neuropathology |
| RML |
Mouse |
120-150 days |
Spongiform vacuolation |
| 79A |
Mouse |
200+ days |
Less vacuolation |
| 22L |
Mouse |
160-180 days |
Cerebellar predominance |
| 301V |
Mouse |
140 days |
Cortical involvement |
When prions cross species barriers:
- Species barrier: Conformational mismatch between host PrP^C and donor PrP^Sc
- Adaptation: Serial passage selects for conformers that replicate in new host
- Mutation: Amino acid differences at interface affect conversion efficiency
- Zoonotic potential: BSE to humans (vCJD) demonstrates cross-species transmission
Current diagnostic markers for prion disease:
-
CSF markers:
- 14-3-3 proteins: Neuronal damage marker
- Tau protein: Elevated in prion disease
- PrP^Sc detection via RT-QuIC
-
Imaging:
- MRI: Cortical ribboning, basal ganglia hyperintensities
- PET: Regional hypometabolism patterns
-
Blood biomarkers:
- Neurofilament light chain (NfL)
- PrP^Sc detection technologies
This ultrasensitive assay detects PrP^Sc in:
- Cerebrospinal fluid
- Skin biopsies
- Blood samples
- Olfactory swab specimens
The RT-QuIC test has revolutionized prion disease diagnosis with >95% sensitivity and specificity.
Gene-silencing approaches:
- Antisense oligonucleotides (ASOs): Target PRNP mRNA for degradation
- RNAi: siRNA-mediated knockdown
- CRISPR-Cas9: Permanent PRNP deletion
Studies in mice show that PrP^C knockout completely prevents prion disease, demonstrating that reducing PrP^C is protective.
Immunotherapeutic approaches:
- Active immunization: PrP-based vaccines
- Passive immunization: Anti-PrP monoclonal antibodies
- Intrabodies: Intracellular antibody fragments
Challenges include:
- Limited antibody access to neurons
- Potential for immune complex formation
- Need for early intervention
Drug candidates targeting conversion:
| Compound |
Mechanism |
Status |
| Quinacrine |
PrP^Sc formation inhibitor |
Clinical trial |
| Pentosan polysulfate |
Lysosomal function |
Phase I |
| Flavonoids |
Aggregate disruption |
Preclinical |
| Doxorubicin |
PrP^Sc clearance |
Preclinical |
- Proteasome activators: Enhance misfolded PrP clearance
- Autophagy inducers: Promote lysosomal degradation
- Chaperone modulators: Improve folding capacity
- UPR modulators: Reduce ER stress
Current therapeutic trials for prion disease:
- Antisense therapy: Ionis Pharmaceuticals developing ASOs targeting PRNP
- Immunotherapy: Various groups pursuing antibody approaches
- Symptomatic treatments: Palliative care for cognitive decline
Induced pluripotent stem cells (iPSCs) from prion disease patients have enabled:
- Patient-specific disease modeling
- Drug screening platforms
- Understanding of cellular vulnerability
- Development of personalized medicine approaches
Adeno-associated virus (AAV) vectors delivering:
- Anti-prion shRNA constructs
- CRISPR components for PRNP editing
- Antibody delivery to CNS
- Gene expression modulators
New biomarker approaches:
- Plasma PrP^Sc detection
- Skin biopsy RT-QuIC
- Salivary biomarkers
- Nasal brush sampling
¶ Understanding Neurotoxicity
Recent work has identified that:
- PrP^Sc oligomers, not fibrils, are the toxic species
- Specific conformational strains correlate with clinical phenotypes
- Cellular PrP^C is required for neurotoxicity
- Synaptic dysfunction precedes neuronal loss
Prion diseases have demonstrated capacity for cross-species transmission:
- BSE (mad cow disease): Transmission to humans as vCJD
- Chronic wasting disease: Potential for cervid-to-human transmission
- Scrapie: No documented human cases, but surveillance continues
Global monitoring includes:
- Animal health monitoring programs
- Human prion disease registries
- Blood donor screening protocols
- Surgical instrument sterilization guidelines
- Beef products restrictions
- Medical device sterilization protocols
- Blood donor deferral
- Animal feed regulations